APEPTICO is developing a portfolio of peptide-based products based on its PEPBASE™ discovery technology.

APEPTICO’s investigational compound solnatide (INN, laboratory code AP301) is a synthetically manufactured peptide, and was originally designed for the therapeutic treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and various forms of life-threatening pulmonary permeability oedema (PPO). Orally inhaled solnatide IMP has completed a first-in-man (FIM) Phase I clinical study, and has delivered clinical proof-of-concept in a randomised, placebo-controlled, double-blinded Phase II clinical study, as well as in a Phase II pilot study in patients suffering from pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and other causes of life-threatening pulmonary dysfunction.

Currently, solnatide is being tested in a phase IIB clinical study for the treatment of life-threatening pulmonary permeability, and is being used for the treatment of severe COVID-19 patients following infection with the new corona virus (SARS-CoV-2).

Read more...